medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2011, Number 04

<< Back Next >>

Ginecol Obstet Mex 2011; 79 (04)

Original articles

Vázquez RLG, Flores GCX

Language: Spanish
References: 26
Page: 183-189
PDF size: 473.58 Kb.


ABSTRACT

Background: HELLP syndrome is associated with more serious cases of preeclampsia-eclampsia with a high frequency of maternal complications
Objective: To report the prevalence and type of maternal complications in patients with HELLP syndrome and to compare these with the recent literature.
Patients and methods: A cross-sectional study was carried out in patients with HELLP syndrome treated between July 1, 2009 and July 31, 2010 in the intensive care unit. Maternal complications were registered in the clinical files. Statistical descriptive measures (averages, median, and standard deviations) and T Student test were used for statistical analysis.
Results: Of a total of 297 patients with P–E, 11.44% (34 cases) corresponded to HELLP syndrome. Prevalence of patients with HELLP syndrome and maternal complications was 35.29% (12 cases) as follows: class I: 16.66% (2 cases), class II: 16.66% (2 cases), class III: 66.68% (8 cases). Average age of patients was 30 ± 6.91 years and gestational age was 32.25 ± 3.64 weeks. Cesarean section was carried out in 91.67% patients (11 cases). Maternal complications included the following: ascites, 21.06%; oligohydramnios, 21.066%; abruptio placentae, 10.53%; multiple organ failure, 10.53%; nosocomial pneumonia, 5.26%; sepsis, 5.26%; acute renal insufficiency, 5.26%; uterine atony, 5.26%; polyhydramnios, 5.26%; eclampsia, 2.94%; placentae senescence 5.26%. There were no maternal deaths.
Conclusions: Frequency of maternal complications was low. Types and distribution were different in relation to those reported in the international literature.


REFERENCES

  1. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;193:859-863.

  2. Díaz de León PMA, Briones GJC, Meneses CJ, Moreno SAA. Microangiopatía trombótica y hemólisis intravascular en hipertensión por embarazo. La mentira del síndrome de HELLP. Cir y Cir 2006;74:211-215.

  3. Baxter JK, Weinstein L. HELLP syndrome: the state of the art. Obstet Gynecol Surv 2004;59:838-845.

  4. Mihu D, Costin N, Mihu CM, Seicean A, Ciortea R: HELLP syndrome –a multisystemic disorder. J Gastrointestin Liver Dis 2007;16:419-424.

  5. Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM. Risk factors for adverse maternal outcomes among women with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000;183:444-448.

  6. Deruelle P, Coudoux E, Ego A, Houfflin-Debarge V, et al. Risk factors for post-partum complications occurring after preeclampsia and HELLP syndrome. A study in 453 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006;125:59-65.

  7. Isler CM, Rinehart BK, Terrone DA, Martin RW, Magann EF, Martin JN Jr. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1999;181:924-928.

  8. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy and Chilbirth 2009;9:8-20.

  9. Castillo GD. Sindrome HELLP. Actualización. Rev Cubana Hematol Inmunol Hemoter. 2007; 23:1-14.

  10. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004;103:981-991.

  11. Kim HY, Sohn YS, Lim JH, Kim EH, et al. Neonatal outcome after preterm delivery in HELLP syndrome. Yonsei Med J 2006;47:393-398.

  12. Thiagarajah S, Bourgeois FJ, Harbert GM, Caudle MR. Thrombocytopenia in preeclampsia: associated abnormalities and management principles. Am J Obstet Gynecol 1984;150:1-7.

  13. Magann EF, Bass D, Chauhan SP, Sullivan DL, Martin RW, Martin JN Jr. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994;171:1148-1153.

  14. Tompkins MJ, Thiagarajah S. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: The benefit of corticosteroids. Am J Obstet Gynecol 1999;181:304-309.

  15. Magann EF, Martin JN. Critical care of HELLP syndrome with corticosteroids. Am J Perinatol 2000; 17: 417-422.

  16. Christy M, Barrilleaux SP, Magann EF, Bass JD, Martin JN. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2001;184:1332-1339.

  17. Martin JN, Thigpen BD, Rose CH, Cushman J, et al. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003;189:830-834.

  18. Solheim LJ, Bernstein PS. High-dose corticosteroids in the treatment of HELLP syndrome. Obstet Gynecol 2004;91:47-50

  19. Sibai BM, Barton JR. Dexamethasone to improve maternal outcome in women with hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Obstet Gynecol 2005;193:1587-1590.

  20. Martin JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006; 195:914-934.

  21. Norma Técnico Médica para la Prevención y Manejo de la Preeclampsia-Eclampsia. México. Dirección de prestaciones médicas. Instituto Mexicano del Seguro Social, 2005.

  22. Guía de Práctica Clínica. Detección y Diagnóstico de Enfermedades Hipertensivas del Embarazo. Dirección de prestaciones médicas. Instituto Mexicano del Seguro Social, 2009.

  23. Martin JN, Rinehart BK, May WL, Magann EF, et al. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999;180:1373-1384.




2020     |     www.medigraphic.com